Not all imatinib resistance in CML are BCR-ABL kinase domain mutations

By Wei Yuan   Hardling Mats   Olsson Bob   Hezaveh Rahil   Ricksten Anne   Stockelberg Dick   Wadenvik Hans  

Annals of Hematology, Vol. 85, Iss. 12, 2006-12 ,pp. : 841-847

Springer Publishing Company

Access to resources Recommend Favorite

Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib

By Chahardouli Bahram   Zaker Farhad   Mousavi Seied Asadollah   Saffari Zeinab   Nadali Fatemeh   Ostadali Mohammadreza   Ghadimi Habibeh   Alimoghaddam Kamran   Ghavamzade Ardeshir   Rostami Shahrbano  

Hematology, Vol. 18, Iss. 6, 2013-11 ,pp. : 327-332

Maney Publishing

Access to resources Recommend Favorite

Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase

By Pattacini L.   Mancini M.   Mazzacurati L.   Brusa G.   Benvenuti M.   Martinelli G.   Baccarani M.   Santucci M.A.  

Leukemia Research, Vol. 28, Iss. 2, 2004-02 ,pp. : 191-202

Elsevier

Access to resources Recommend Favorite

The tyrosine kinase inhibitor STI571, like interferon- , preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

By Marley S.B.   Deininger M.W.N.   Davidson R.J.   Goldman J.M.   Gordon M.Y.  

Experimental Hematology, Vol. 28, Iss. 5, 2000-05 ,pp. : 551-557

Elsevier

Access to resources Recommend Favorite

Acute myeloid/NK precursor cell leukemia with trisomy 4 and a novel point mutation in the extracellular domain of the G-CSF receptor in a patient with chronic idiopathic neutropenia

By Papadaki H.  

Annals of Hematology, Vol. 83, Iss. 6, 2004-06 ,pp. : 345-348

Springer Publishing Company

Access to resources Recommend Favorite